Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 147 In stock
USD 370 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 62 Publications

10 Customer Reviews

  • Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

Purity & Quality Control

Choose Selective Src Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 NXnEcVlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\tUVczKGh? M1nDcmROW09? MX;JR|UxRTBwMECwNFch|ryP M3TBcVE4QTV4MEiw
K562 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7LdZp3PzJiaB?= NW\QW4RoTE2VTx?= NIr5boZKSzVyPUCuNFAyKM7:TR?= NH34U3kyPzl3NkC4NC=>
M07e M1XuO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYGzfmg{PzJiaB?= M1LveGROW09? NWfjSYxlUUN3ME2wMlAxOTJizszN NUDwVHA2OTd7NU[wPFA>
ALL3 MmXrR5l1d3SxeHnjJGF{e2G7 M2TrfFAvOc7:TR?= MVK3NkBp MVXEUXNQ M1Hhe2lEPTB;MD6wNFA1KM7:TR?= M{e0O|E6QDh7NUSw
CML MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zDd|IxKG2rbh?= MnnFSG1UVw>? NFfKZopKSzVyPUCuNFAyKM7:TR?= MXSxPVIyQTBzNh?=
BA/F3 M1njbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3pO|VGPzJiaB?= Mk\ESG1UVw>? MWPJR|UxRTZwNUi5JO69VQ>? NWqydo02OjNyOEi2OFQ>
BA/F3 M{fEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYm3NkBp NVvPWWVFTE2VTx?= MorsTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegRoNzNUGkbDDNN|UyXCCvdYThcpQhf2m2aDDJR|UxKG:oIECuNFAxQDQQvF2= MXmyN|A5QDZ2NB?=
BA/F3 MlvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVe4NIFrPzJiaB?= M3voVGROW09? MXLJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzD3bYxlKHS7cHWgRoNzNUGkbDD3bZRpKEmFNUCgc4YhOC5yMES1{txO NIfYZoYzOzB6OE[0OC=>
BA/F3 M4nYPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHucVlxPzJiaB?= NH:3bG5FVVOR NWj4[3hjUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBVOzF3STDteZRidnRid3n0bEBKSzVyIH;mJFEvPzF2zszN MVWyN|A5QDZ2NB?=
BA/F3 NVO5ZWZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoH4O|IhcA>? MX3EUXNQ MVPJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBHPDh4UzDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECwPe69VQ>? MkPNNlM{ODF5MEO=
BA/F3 MlmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LC[lczKGh? NIj4cVJFVVOR NIPTNpZKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHMkW1T{BufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA{Os7:TR?= NWjPd5lrOjN|MEG3NFM>
BA/F3 NWPwNIFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33Bb|czKGh? MlHpSG1UVw>? NXXXTGNjUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiR{K1NGUhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxPTIQvF2= NGCw[4EzOzNyMUewNy=>
BA/F3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVS3NkBp MVXEUXNQ MUDJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBSOjV{SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC4{txO MY[yN|MxOTdyMx?=
BA/F3 M2LNW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX[3NkBp M{O5[GROW09? MkGxTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTN3OW[gcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVPPxE1? NFvGboszOzNyMUewNy=>
BA/F3 NWL3UXpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Pw[|czKGh? M4jmVGROW09? M2GzRWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViQlPSMWFDVCCjc4Pld5Nm\CCjczDndo94fGhiSX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOC5yMEG5{txO M1nmNFI{OzBzN{Cz
BA/F3 NYPrOVRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFS4cIc4OiCq MkfCSG1UVw>? M{PFcGlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFl{NUPIJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFI{|ryP M3;qPVI{OzBzN{Cz
BA/F3 M3fxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYOwT5NjPzJiaB?= MXnEUXNQ MVXJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBVOzF3STDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDNwNt88US=> M3ruWVI{OzBzN{Cz
BA/F3 M13PUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\YdGY4OiCq MWDEUXNQ NYDQSWxiUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiSX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOi53zszN MVOyN|MxOTdyMx?=
T cell MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUW5ToVtPzJiaB?= NEXhU4lFVVOR M1u4RWlvcGmkaYTzJIFvfGliQ1SzMUBidmRiYX70bUBETDJ6LXnu[JVk\WRiVDDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMECz{txO NIO4[pUyPzF3NEWxNi=>
WiDr MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\0SWlHPzJiaB?= NEfadVRFVVOR Mor2TWM2OD1yLkC1NkDPxE1? M3vvUVE2PjF3NUGy
PC3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnmO|IhcA>? MkXpSG1UVw>? NUf6eHFbUUN3ME2wMlAxQTRizszN NX3q[W9kOTV4MUW1NVI>
MDA-MB-231 NHzmNI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rjRVczKGh? M1XYdGROW09? MUnJR|UxRTBwMEGyJO69VQ>? NFXEW|QyPTZzNUWxNi=>
Hs578T MVHDfZRwfG:6aXOgRZN{[Xl? M1SxNlczKGh? MUjEUXNQ M1K5UmdKPTB;MD6wN{DPxE1? NVvnSolTOjRyMUWzNlc>
HMEC NWXTSm9lS3m2b4TvfIlkKEG|c3H5 MUO3NkBp NVzn[oc6TE2VTx?= NY\nZoxFT0l3ME2xMlgh|ryP Mn\DNlQxOTV|Mke=
DU145 NIjVTYVEgXSxdH;4bYMhSXO|YYm= MVu3NkBp M{K3cmROW09? MnvjS2k2OD1yLkG2JO69VQ>? MXiyOFAyPTN{Nx?=
U251 NIe3NHFEgXSxdH;4bYMhSXO|YYm= NWLGSJJXPzJiaB?= M3\1cGROW09? NVTaUlY4T0l3ME2yMlgyKM7:TR?= NX60PVN6OjRyMUWzNlc>
NCI60 Mn3UR5l1d3SxeHnjJGF{e2G7 NVXwOoVPPzJiaB?= MmLrSG1UVw>? NXH2d21rT0l3ME21Mlch|ryP NF\0fWkzPDBzNUOyOy=>
MALME-3M M4\ydmN6fG:2b4jpZ{BCe3OjeR?= NUK3fpYzPzJiaB?= NUPW[HlvTE2VTx?= NGXEeXhIUTVyPU[uOlEh|ryP NUHyS4pROjRyMUWzNlc>
KM12 NFjBOppEgXSxdH;4bYMhSXO|YYm= NH7rWnQ4OiCq NW\jZVZQTE2VTx?= MnHUS2k2OD15LkS0JO69VQ>? NV[1b4I5OjRyMUWzNlc>
SW620 M2PBWWN6fG:2b4jpZ{BCe3OjeR?= MUK3NkBp MXLEUXNQ NG\ifoxIUTVyPUiuOFMh|ryP NX62TYU5OjRyMUWzNlc>
RXF 393NL NFOzWFREgXSxdH;4bYMhSXO|YYm= NVnhWHVGPCCmYYnz NWfVR3N3TE2VTx?= NWT5coF7UUN3ME2wMlAzOTdizszN NYCyXZhXOjN{NUOwO|Q>
LXFA 983L MnrTR5l1d3SxeHnjJGF{e2G7 M1LvOFQh\GG7cx?= MmXuSG1UVw>? NHv5S5FKSzVyPUCuNFU3PSEQvF2= M4DFb|I{OjV|MEe0
PRXF DU145 MofGR5l1d3SxeHnjJGF{e2G7 NYDmbFI1PCCmYYnz MljWSG1UVw>? MlTpTWM2OD1yLkC2NlMh|ryP NX\TeJN3OjN{NUOwO|Q>
PAXF 1657L MkfJR5l1d3SxeHnjJGF{e2G7 MnG4OEBl[Xm| NEjicpFFVVOR NWXXVGpFUUN3ME2wMlEzOSEQvF2= M1zqZVI{OjV|MEe0
CXF 1103L MlzxR5l1d3SxeHnjJGF{e2G7 MUW0JIRigXN? Ml3ISG1UVw>? MV;JR|UxRTRwM{[g{txO M1XzNFI{OjV|MEe0
GXF251L NWWxe4x{S3m2b4TvfIlkKEG|c3H5 NFKzfJc1KGSjeYO= NYXzeJJJTE2VTx?= NUThd2dOUUN3ME2yMlI2KM7:TR?= Mo\ONlMzPTNyN{S=
NCI-H23 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrDcHQ4OiCq NEe3W3JFVVOR M2DyNWlEPTB;Mj6yO{DPxE1? NXjJV4xEOjN3MkGwNlA>
HCT116 M4nrd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWi2XFFOPzJiaB?= M3rGNGROW09? M4O2XmlEPTB;Mj6zJO69VQ>? NXjRUphKOjN3MkGwNlA>
MCF7 M3;qOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVK3NkBp MVHEUXNQ MYfJR|UxRTJwNUeg{txO NYHNcYxvOjN3MkGwNlA>
NCI-H460 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInlZVE4OiCq MWDEUXNQ M{fvfWlEPTB;OD65PUDPxE1? M3zzUFI{PTJzMEKw
DLD1 NVXsNYNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVG3NkBp NX\UcI06TE2VTx?= NGTRfZlKSzVyPUSuOkDPxE1? NG\GeoczOzV4N{m2NC=>
NCI-H661 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX[3NkBp NE\kZllFVVOR NHvQbG9KSzVyPUeuPEDPxE1? M3;ibFI{PTZ5OU[w
A549 NI[xOIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PzcVczKGh? M125TmROW09? MnO2TWM2OD16LkKg{txO NEGySm8zOzV4N{m2NC=>
U937 NGHFTGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4npfFczKGh? MkHtSG1UVw>? MX3JR|UxRTF{LkKg{txO M373WlI{PTZ5OU[w
HEK293 MX7GeY5kfGmxbjDBd5NigQ>? M4DHXVExyqEQvF2= MWTEUXNQ M2T3WGlv\HWlZYOgZolv\GmwZzDh[oZqdmm2eTD0c{BpfW2jbjDmeYxtNWynbnf0bEBJcXNvdHHn[4VlKE27dEGgb4lv[XOnIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNid3n0bEBKSzVyIH;mJFAvODZ|zszN M2XycFIzPzdyNkGw
HUVEC NWjqdph[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTvNE4yPcLizszN NIjNdJk4OiCq NEjpb3BFVVOR MmXnTY5lfWOnczDhcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGSyClbz3jeYx1fXKnZDD3bZRpKH[jc3P1cIFzKHOvb3;0bEBufXOlbHWgZ4VtdHNiYYPz[ZN{\WRiYYOgTY5pcWKrdHnvckBw\iClZXzsJIdzd3e2aDDheEAxNjF3IIXN Mo\ENlI5PTN7OUO=
HUVEC M1XtTWZ2dmO2aX;uJGF{e2G7 MmC3NVXDqM7:TR?= NYrlTnRMPzJiaB?= NFfQTWNFVVOR M2PVVGlv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC|bX;veIghdXW|Y3zlJINmdGy|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZibnX0e49zcyCob4LtZZRqd25iYYSgNU45KHSxIEG1JJVO MmroNlI5PTN7OUO=
Plasmodium falciparum MoLTSpVv[3Srb36gRZN{[Xl? NXniVnZJOTEEoN88US=> NFPUbmEyPSCvaX6= MoPiSG1UVw>? M3LMemlvcGmkaYTzJHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCycn;sbYZmemG2aX;uJIJ6KGmwaHnibZRqdmdidHjlJGZ2dmO2aX;uJI9nKFCoQ1TQT|EheHKxdHXpckB4cXSqIFnDOVAhd2ZiMT6xO:69VQ>? NF;RW|UzPDV3MEOzNC=>
PC3 NXrGU3hLTnWwY4Tpc44hSXO|YYm= MYqwMlEh|ryP M3\pelUhcA>? Ml30SG1UVw>? MoXXTY5pcWKrdIOgbJVu[W5iUFOzJINmdGxiYXTo[ZNqd25iYYSgNVAxKG6P M13GNFE6PDZ{OUe1
DU145 M2X5WWZ2dmO2aX;uJGF{e2G7 MVOwMlEh|ryP MoDkOUBp NG\uUYlFVVOR NFKzR2xKdmirYnn0d{BpfW2jbjDEWVE1PSClZXzsJIFlcGW|aX;uJIF1KDFyMDDuUS=> M4Hq[|E6PDZ{OUe1
PC3 M37vVmtqdmG|ZTDBd5NigQ>? MV6wMlEh|ryP NH\t[5k2KGh? Ml7SSG1UVw>? NF3FN3FKdmirYnn0d{BkW3KlIHnuJIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhW3KlIGm0NVYhdGW4ZXygZZQhOTByIH7N Ml7qNVk1PjJ7N{W=
DU145 M1\VRmtqdmG|ZTDBd5NigQ>? MUSwMlEh|ryP MkLYOUBp M1HmRmROW09? NF\KbmRKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCVcnOgXVQyPiCuZY\lcEBifCBzMECgcm0> NH\YNZgyQTR4Mkm3OS=>
PC3 NXf0b2hxU2mwYYPlJGF{e2G7 M3f2XVAvOSEQvF2= MkjoOUBp MkmySG1UVw>? NWno[21XUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDQR|Mh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKE[DSzDZOVc3N1l3N{egcIV3\WxiYYSgNVAxKG6P MYexPVQ3Ojl5NR?=
DU145 MnziT4lv[XOnIFHzd4F6 MYewMlEh|ryP MUm1JIg> Mnm0SG1UVw>? MmrRTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhTkGNIGm1O|YwYTV5NzDs[ZZmdCCjdDCxNFAhdk1? M173OFE6PDZ{OUe1
Huh7 NHXmdmFCdnSrdnnyZYwhSXO|YYm= M3jRZ|IvPSEQvF2= MXO0JIRigXN? NF[4OWVFVVOR M2HLb2lvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQhcHWvYX6gTJVpPyClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TR?= NUHIeotVOTd|NkC2O|Y>
C6/36 M2Py[2FvfGm4aYLhcEBCe3OjeR?= NVPoNnNjOi53IN88US=> NVL5TGFVPCCmYYnz M4TXWGROW09? NVTkcY1iUW6qaXLpeJMhfmm{YXygd5Bz\WGmIHnuJGRmdme3ZTD2bZJ2ey2rbn\lZ5Rm\CCjc3nhckB1cWencjDtc5NyfWm2bzDDOk8{PiClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TR?= M4S3UFE4OzZyNke2
U937 NULwWJdJTnWwY4Tpc44hSXO|YYm= NYnpcFRQOSEQvF2= MWSxJIg> NHfNO2FFVVOR NXj0S3JwWmWmdXPld{Bj[XOjbDDUUmZidHCqYTDy[Yxm[XOnIHnuJIh2dWGwIGW5N|ch[2WubIO= NGrDOYIyPzZ6NEC5PS=>
U937 NYr0OlFqTnWwY4Tpc44hSXO|YYm= M{XRc|Eh|ryP M1PmZlEhcA>? NWDVO3lHTE2VTx?= MnW0VoVlfWOnczDMVHMucW6mdXPl[EBVVk[jbIDoZUBz\WynYYPlJIlvKGi3bXHuJHU6OzdiY3XscJM> NWjq[Y93OTd4OESwPVk>
murine mast cell MUTGeY5kfGmxbjDBd5NigQ>? NHH5WpcyKM7:TR?= NEfRO|AzPCCq M1LiZmROW09? MUHJcohq[mm2czDhcpRq\2WwLXnu[JVk\WRiSVy2JJNm[3KndHnvckBqdiCLZ1WgdJJqdWWmIH3veZNmKG2jc4SgZ4VtdHNiYYSgNUB2VQ>? MnPyNVc3QDRyOUm=
BV-173 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlGxTWM2OD1yLkCwNFAxODFyOTFOwG0> M{DCWnNCVkeHUh?=
K-562 NUDZcFdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;s[GlEPTB;MD6wNFAxODB{Nk[g{txO NIT5Xo9USU6JRWK=
BL-70 NX;jTJV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoS3TWM2OD1yLkCwNFAxODh{MjFOwG0> NFPDfItUSU6JRWK=
EM-2 MlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnHS4RoUUN3ME2wMlAxODByMUC4JO69VQ>? NVHlPW5DW0GQR1XS
LAMA-84 NUnFU|BoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2ToTGlEPTB;MD6wNFAxODN{MTFOwG0> NXrJflBLW0GQR1XS
MEG-01 MmjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XObGlEPTB;MD6wNFAxODl6IN88US=> MX\TRW5ITVJ?
EoL-1-cell NGfNWJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwMECwNFE{OSEQvF2= NH\6[GRUSU6JRWK=
CTV-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13qfGlEPTB;MD6wNFAxPDB2IN88US=> MlvzV2FPT0WU
TE-15 NH;XU4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnrOGNpUUN3ME2wMlAxPTh7IN88US=> MV;TRW5ITVJ?
NOS-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\KOGVKSzVyPUCuNFA3OTNizszN MX3TRW5ITVJ?
D-336MG Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXH1WZg6UUN3ME2wMlAxPjNizszN NHrndW9USU6JRWK=
LB1047-RCC MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnyVYtiUUN3ME2wMlAxQTh7IN88US=> MUfTRW5ITVJ?
LB996-RCC NYjiN2FPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\2TWM2OD1yLkCwPVkyKM7:TR?= NF20SZNUSU6JRWK=
SW982 NGPLVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfK[IlKSzVyPUCuNFEyOTVizszN MVfTRW5ITVJ?
TK10 M{PHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwMEGxO|Qh|ryP MmDnV2FPT0WU
A704 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\LbHVqUUN3ME2wMlAyPDlzIN88US=> M4nROXNCVkeHUh?=
TE-8 MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mme2TWM2OD1yLkCxOVc3KM7:TR?= MWjTRW5ITVJ?
DOHH-2 NXLPd2hiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33WVmlEPTB;MD6wNVcyQSEQvF2= NFfEeIxUSU6JRWK=
HOP-62 NGnBTGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIP2ZnpKSzVyPUCuNFE5OzRizszN NWO5dHp5W0GQR1XS
TE-12 M4HM[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjnTHdKSzVyPUCuNFE5PjFizszN NFP0dnBUSU6JRWK=
KGN NHnKdVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPOWnpKSzVyPUCuNFE6PDJizszN MmjlV2FPT0WU
NCI-H1648 NIjKc3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwMEKwNVEh|ryP NWP0TXZUW0GQR1XS
OS-RC-2 NVruV4tFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwMEKwN{DPxE1? MnTJV2FPT0WU
GB-1 NWPQTo5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2ewcWlEPTB;MD6wNlE2PyEQvF2= NVjNWnJtW0GQR1XS
RXF393 M3PzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nucmlEPTB;MD6wNlM2PyEQvF2= NGm1e2dUSU6JRWK=
LC-2-ad MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H1cWlEPTB;MD6wNlU5PiEQvF2= M1fnSHNCVkeHUh?=
KS-1 M{K4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDHfHFQUUN3ME2wMlAzPzNizszN NIrQSmRUSU6JRWK=
ETK-1 MlThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\CS2lEPTB;MD6wNlg{OiEQvF2= NILUWXZUSU6JRWK=
SW954 NEX2bWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELYWYhKSzVyPUCuNFI6OjdizszN MkLkV2FPT0WU
Becker Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjVcmhKSzVyPUCuNFMxODNizszN NUnwUpVWW0GQR1XS
MZ1-PC MlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{e5fWlEPTB;MD6wN|EyQSEQvF2= M{L5SnNCVkeHUh?=
ES6 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwMEOxPVMh|ryP MWDTRW5ITVJ?
KURAMOCHI NWLLWWdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[2TWM2OD1yLkCzOFg4KM7:TR?= MV;TRW5ITVJ?
CGTH-W-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrOTWM2OD1yLkCzOVQ5KM7:TR?= M2\ud3NCVkeHUh?=
VA-ES-BJ NXjBZZZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3n0TWlEPTB;MD6wN|kxOiEQvF2= NFG2cpdUSU6JRWK=
LXF-289 NIXqUHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrQ[nZKSzVyPUCuNFM6PTZizszN NV;ZbXpCW0GQR1XS
MPP-89 NGXTbJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnpeHQ5UUN3ME2wMlA1ODR7IN88US=> MWPTRW5ITVJ?
SW872 MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwMESxOlEh|ryP M332[XNCVkeHUh?=
SNB75 NH:1SXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwMES0N|Uh|ryP NWjEcpU4W0GQR1XS
PSN1 M4\sbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLLN5JKUUN3ME2wMlA1PDd2IN88US=> MYPTRW5ITVJ?
LB831-BLC NYXDU45{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwMES2NFkh|ryP NGm4NXBUSU6JRWK=
MFH-ino MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[3d4s4UUN3ME2wMlA1PzJ2IN88US=> NGj1SFlUSU6JRWK=
TGBC24TKB NUG4V2txT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwMES3OlEh|ryP NIXSOWRUSU6JRWK=
A388 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrvTWM2OD1yLkC1NFk2KM7:TR?= MUfTRW5ITVJ?
BB30-HNC MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXBXmZqUUN3ME2wMlA2PDN5IN88US=> MVHTRW5ITVJ?
GI-ME-N NH3vfGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDsTWM2OD1yLkC2NVE5KM7:TR?= M3vPO3NCVkeHUh?=
TGBC1TKB NIjBN|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37WVmlEPTB;MD6wOlE3PCEQvF2= NY\meXA5W0GQR1XS
TE-10 NUO3bGIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwME[zOVch|ryP NEnnV3lUSU6JRWK=
A498 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGm3eoxKSzVyPUCuNFczQDRizszN M4XoeXNCVkeHUh?=
TE-11 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\yRpg4UUN3ME2wMlA4QDV6IN88US=> M4PBZ3NCVkeHUh?=
BB65-RCC M2qyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwMEiyNlch|ryP MmnNV2FPT0WU
C2BBe1 NEG1UFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;nTWM2OD1yLkC4N|A5KM7:TR?= NEnoUXBUSU6JRWK=
NCI-H747 NXvxNY15T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLRTWM2OD1yLkC4N|YzKM7:TR?= M37iTXNCVkeHUh?=
IST-MES1 NVvEN|FzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYG4To1FUUN3ME2wMlA5PTV{IN88US=> MmLxV2FPT0WU
KALS-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwMEm0PUDPxE1? M2[0TnNCVkeHUh?=
GCIY NHjNelRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1G4VGlEPTB;MD6wPVY2PiEQvF2= NYrPdFFmW0GQR1XS
RL95-2 MlP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\GOWFlUUN3ME2wMlExOzhizszN M{ezbnNCVkeHUh?=
TE-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnNSHduUUN3ME2wMlExPTRizszN MXvTRW5ITVJ?
NCI-H1355 NGfoNnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwMUGwNlgh|ryP NYDlNmdCW0GQR1XS
SW962 NWO0dngzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYO1eGF7UUN3ME2wMlEyOjl{IN88US=> NWfpcmh5W0GQR1XS
KLE NG\NUllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHX2TplKSzVyPUCuNVE{OTdizszN MUHTRW5ITVJ?
MC116 NU\IUlRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwMUG0NUDPxE1? NGrDfXRUSU6JRWK=
NMC-G1 M2\tTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTkTWM2OD1yLkGxOlA3KM7:TR?= NVHyNFl2W0GQR1XS
KU812 NEHUbHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvNOI9KSzVyPUCuNVE5QDNizszN MkfFV2FPT0WU
COLO-829 MkDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvoVopKSzVyPUCuNVIzOTNizszN NH;ndllUSU6JRWK=
NTERA-S-cl-D1 NETTeWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwMUKyPFMh|ryP MmPMV2FPT0WU
IST-MEL1 MnnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTBwMUO0OUDPxE1? MmH6V2FPT0WU
MLMA Ml35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwMUSwN|Ih|ryP MULTRW5ITVJ?
LS-123 M3XBfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwMUSwOlQh|ryP MXHTRW5ITVJ?
LB2518-MEL Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3DPXFmUUN3ME2wMlE1OTZ{IN88US=> MkHDV2FPT0WU
NB69 NHT0RVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk[0TWM2OD1yLkG0OFM3KM7:TR?= MmHhV2FPT0WU
8-MG-BA M1m5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwMUW0OVgh|ryP NH;DNldUSU6JRWK=
K5 MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLPTWM2OD1yLkG2OFg6KM7:TR?= MWHTRW5ITVJ?
KINGS-1 M{nn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMU[2OlYh|ryP NETXVIRUSU6JRWK=
SF268 NF[wcHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:0TmlEPTB;MD6xO|QxPCEQvF2= MoLoV2FPT0WU
PF-382 M2L4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HNPWlEPTB;MD6xO|Y4QCEQvF2= MmXpV2FPT0WU
SH-4 M2iwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFy2U3JKSzVyPUCuNVg1OTNizszN MWXTRW5ITVJ?
NALM-6 MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jFcGlEPTB;MD6xPVI6PSEQvF2= NEPmcZJUSU6JRWK=
CP66-MEL MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfXfXVbUUN3ME2wMlE6PTNzIN88US=> NXnQcYFmW0GQR1XS
697 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnv3TWM2OD1yLkG5PVg4KM7:TR?= NELsOm9USU6JRWK=
CP67-MEL M1;qTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwMkC0PFgh|ryP MUXTRW5ITVJ?
DSH1 NFvXflJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfkVolJUUN3ME2wMlI1ODBzIN88US=> MmTKV2FPT0WU
HCE-4 Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPCWVRKSzVyPUCuNlY1OzlizszN NVnPNIQ2W0GQR1XS
MZ2-MEL NXHXSIdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIj3bHRKSzVyPUCuNlg2OzdizszN NEnJWYNUSU6JRWK=
BL-41 NHO4WlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnkPYRKSzVyPUCuNlkyOjNizszN NUXneHVJW0GQR1XS
HUTU-80 NXTZ[FlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nLWmlEPTB;MD6zNVQzKM7:TR?= NXL3[GNHW0GQR1XS
LOXIMVI NFn4SIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwM{G1NFMh|ryP NYfwVW9bW0GQR1XS
no-10 NFHlSXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvVcJRTUUN3ME2wMlMyQTNzIN88US=> MmXxV2FPT0WU
KARPAS-422 M13TZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M36wdmlEPTB;MD6zN|k6PyEQvF2= NF\QS|dUSU6JRWK=
SW684 MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHHUYlVUUN3ME2wMlM1QThizszN MnPWV2FPT0WU
SF126 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwM{W0NUDPxE1? NFT3fVJUSU6JRWK=
D-263MG Mnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwM{[yNlQh|ryP NEHhRY9USU6JRWK=
OVCAR-4 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTBwM{e0N|Mh|ryP NYrPe3N7W0GQR1XS
BB49-HNC NVXTcmlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\WS4pDUUN3ME2wMlM5PTl7IN88US=> NGDJUlFUSU6JRWK=
ONS-76 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrpbHZYUUN3ME2wMlQzQTVzIN88US=> M2rQdHNCVkeHUh?=
MZ7-mel M4nv[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInsPHdKSzVyPUCuOFc6OTFizszN NGq0[o9USU6JRWK=
RCC10RGB M{HHXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLqXZVLUUN3ME2wMlQ6OTFizszN NIHyXlRUSU6JRWK=
BOKU MoHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfnTWM2OD1yLkS5NVM{KM7:TR?= MVTTRW5ITVJ?
no-11 NIH4S4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfPTWM2OD1yLkWwNlI5KM7:TR?= Mn3CV2FPT0WU
IST-SL2 M1[xPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LXdWlEPTB;MD61NFMxOiEQvF2= MlH5V2FPT0WU
RKO MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfzTWM2OD1yLkWyPVY3KM7:TR?= Mlu0V2FPT0WU
HT-144 M{PUSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfIR|VxUUN3ME2wMlU{PjB7IN88US=> NGrBSpNUSU6JRWK=
NCI-H446 M{joVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwNkK3OkDPxE1? MonkV2FPT0WU
QIMR-WIL MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwN{C2Nlkh|ryP MorSV2FPT0WU
MHH-PREB-1 M2DzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;mXmlEPTB;MD63OFQ3QSEQvF2= NHTHV4FUSU6JRWK=
EW-16 NX3DXW1FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwN{[xO|gh|ryP NGjHSm9USU6JRWK=
EW-24 NIrOdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXG2dG44UUN3ME2wMlc5OTZ3IN88US=> NFvzT|dUSU6JRWK=
LB373-MEL-D MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWSwbm9lUUN3ME2wMlgzPTB6IN88US=> M3Xad3NCVkeHUh?=
TE-9 M4j2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYS1[4RVUUN3ME2wMlg4PTN{IN88US=> M2C4OnNCVkeHUh?=
A3-KAW NHvBdJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fCXmlEPTB;MD65PFQ2OiEQvF2= NGfo[FBUSU6JRWK=
A101D NV;xNG5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fH[WlEPTB;MT6wN|A1OyEQvF2= MlXZV2FPT0WU
OCUB-M NYPU[m5DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PnVmlEPTB;MT6wOFQyOiEQvF2= NWHMW|NjW0GQR1XS
ES4 NFK0VIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHNWFdKSzVyPUGuNFUyPDVizszN M{fXcnNCVkeHUh?=
TE-6 NWPFOnBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX:4WHp1UUN3ME2xMlIyOjJ4IN88US=> MW\TRW5ITVJ?
D-502MG NFLlXXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnH4TWM2OD1zLkKzN|c3KM7:TR?= MnjJV2FPT0WU
KNS-42 M2TmSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfVTWM2OD1zLkK0OFEzKM7:TR?= MoD1V2FPT0WU
SNU-C2B M1S1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3r5V2lEPTB;MT6zNFU5QSEQvF2= M1;GSXNCVkeHUh?=
NCI-H1838 NETkOWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TIXWlEPTB;MT6zNFc{OyEQvF2= M1PNV3NCVkeHUh?=
NKM-1 M3LVUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTFwM{C4OVkh|ryP MX;TRW5ITVJ?
GI-1 NVi5OZNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTFwM{[yNkDPxE1? NHLGXG5USU6JRWK=
NB5 NHriTlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPEdFBKSzVyPUGuN|k5OjdizszN M2PUU3NCVkeHUh?=
CAS-1 M4nwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HCRWlEPTB;MT60NFk6OiEQvF2= NUfifWNjW0GQR1XS
HCE-T M3jO[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYH0S4lNUUN3ME2xMlU3PzF2IN88US=> M{PSU3NCVkeHUh?=
SBC-1 NUTsOlZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3ub|A6UUN3ME2xMlU4QTh2IN88US=> NITO[4FUSU6JRWK=
JiyoyeP-2003 MlezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTFwN{O0OlYh|ryP Mo\1V2FPT0WU
TE-5 M2DwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnufWJKSzVyPUGuO|kyOzlizszN MVzTRW5ITVJ?
CAN Ml;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLPOlVKSzVyPUGuPFIzPTJizszN MnPwV2FPT0WU
SK-UT-1 NFTEUWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHP3ZoxKSzVyPUKuNVY3QTNizszN MXrTRW5ITVJ?
JVM-2 M{jLNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTJwM{[yPFQh|ryP MV3TRW5ITVJ?
LB771-HNC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TFZmlEPTB;Mj61O|U2OSEQvF2= MX\TRW5ITVJ?
NCCIT NUHn[2JYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTJwOE[2NVYh|ryP NXPPSYgyW0GQR1XS
NCI-H2126 MnnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mny0TWM2OD1{Lki3OVUzKM7:TR?= NFTh[oVUSU6JRWK=
Calu-6 MojOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFm2fm9KSzVyPUOuNFU4PDFizszN MYTTRW5ITVJ?
SK-LMS-1 M4L2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFj6bmpKSzVyPUOuNVE5QDZizszN MYrTRW5ITVJ?
ARH-77 NFraTHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDnT3RGUUN3ME2zMlQ3QTF3IN88US=> M1;STHNCVkeHUh?=
NB17 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTNwNkO4OFch|ryP NYjiXowzW0GQR1XS
A253 M1\BcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTNwN{OyOFYh|ryP MX;TRW5ITVJ?
OPM-2 NInWTpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHDXGtKSzVyPUSuNlc3QDVizszN MVTTRW5ITVJ?
MV-4-11 MnPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvDOGIyUUN3ME20MlM3PDV2IN88US=> MXXTRW5ITVJ?
SR M3mzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHflNpRKSzVyPUSuOFk6PTRizszN M1XoTnNCVkeHUh?=
KG-1 M17rWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnj0TWM2OD12Lk[wPFQ2KM7:TR?= MVLTRW5ITVJ?
OCI-AML2 M3LzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTVwOE[xOVQh|ryP MoXjV2FPT0WU
D-247MG MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DqWWlEPTB;Nj6xNlUyQSEQvF2= NX7jeZNkW0GQR1XS
DJM-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvuTWM2OD14LkS4OVU5KM7:TR?= NFjaVWhUSU6JRWK=
RPMI-6666 NGTIN4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13OdWlEPTB;Nz6yO|A3PyEQvF2= NF3PZYtUSU6JRWK=
KARPAS-45 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7lOYFKSzVyPUeuOVE3PzFizszN M2frOHNCVkeHUh?=
LP-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13RNGlEPTB;Nz61OFc5OiEQvF2= MV\TRW5ITVJ?
RS4-11 NHvifmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Pvd2lEPTB;Nz62OVc5PyEQvF2= Mn;XV2FPT0WU
DU-4475 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRThwMkG2OVIh|ryP NFnWXGJUSU6JRWK=
MONO-MAC-6 MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnntTWM2OD16LkK3NFY3KM7:TR?= MnPvV2FPT0WU
NCI-SNU-16 MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fTXmlEPTB;OD61OlEzQCEQvF2= Mle2V2FPT0WU
SJSA-1 NVvnTlFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWD5cpVOUUN3ME24MlczQDB3IN88US=> M1G4b3NCVkeHUh?=
MMAC-SF NVW5dJY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XvbGlEPTB;OD63PVMxPyEQvF2= M1jBcHNCVkeHUh?=
SK-NEP-1 M3vPfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYK3WlUxUUN3ME24Mlg6OTV3IN88US=> NHvK[3NUSU6JRWK=
J-RT3-T3-5 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HQOmlEPTB;OD65OlUzQSEQvF2= MYfTRW5ITVJ?
SKM-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;IfGd4UUN3ME25MlAyPzN2IN88US=> M{XiWHNCVkeHUh?=
LB2241-RCC NXvwfYhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYr3[G5qUUN3ME25MlAzODF{IN88US=> NGHEcZJUSU6JRWK=
SIG-M5 NUfxNJNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjWbmlnUUN3ME25MlAzPDl|IN88US=> MV7TRW5ITVJ?
EVSA-T NVTQVFVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\FTWlEPTB;OT6yO|c6OyEQvF2= NUT6XIN1W0GQR1XS
GT3TKB NVrucWt2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTlwM{W1OFYh|ryP M3GxNHNCVkeHUh?=
NB6 M1POSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnITWM2OD17LkmyNlU6KM7:TR?= M3\zPXNCVkeHUh?=
EHEB MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjMTWM2OD1zMD6wOlU3KM7:TR?= MVfTRW5ITVJ?
HEL MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnp[VdKSzVyPUGwMlQ4PzZizszN NFfxW4dUSU6JRWK=
ALL-PO NE\3UFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\OZZdKSzVyPUGwMlc6OzhizszN MUHTRW5ITVJ?
TGW M{fSUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTFzLkK4Nlgh|ryP MmXzV2FPT0WU
BC-3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDLTWM2OD1zMj6xNVM5KM7:TR?= M3;aVHNCVkeHUh?=
IA-LM M1\nPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTF{LkS0OFUh|ryP MYjTRW5ITVJ?
UACC-257 NIXGXo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTF{LkmxPVgh|ryP MkPKV2FPT0WU
KP-N-YS NH\hTndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\nTWM2OD1zMj65Nlg{KM7:TR?= MoW1V2FPT0WU
Raji NEjTbJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWC1cJdxUUN3ME2xN{44PDl5IN88US=> NWK2WFdXW0GQR1XS
SF539 MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELwbYJKSzVyPUGzMlg2PTdizszN NYj2foV6W0GQR1XS
DMS-153 MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknlTWM2OD1zND6wNFI5KM7:TR?= NEXWdopUSU6JRWK=
L-540 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlu1TWM2OD1zNT6wOlczKM7:TR?= MWjTRW5ITVJ?
MN-60 M2PKUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHETWM2OD1zNT6xPVc6KM7:TR?= NGLK[2xUSU6JRWK=
RPMI-8866 MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHtTWM2OD1zNz60OFU1KM7:TR?= M1\B[3NCVkeHUh?=
NCI-H510A NH\Sc2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkn0TWM2OD1zOT6zPVc{KM7:TR?= MVvTRW5ITVJ?
NB13 NYHQT5dlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnETWM2OD1zOT60PFc4KM7:TR?= M1TtVXNCVkeHUh?=
HAL-01 MnzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXpTWM2OD1zOT63OVQ{KM7:TR?= M3\HNnNCVkeHUh?=
NCI-H720 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXYTWM2OD1{MD6yO|M{KM7:TR?= M{LvfHNCVkeHUh?=
REH M3PDbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnzfoZKSzVyPUKwMlY{PTdizszN NWDqbJl4W0GQR1XS
KNS-81-FD NEG3OpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\4bGlEPTB;MkOuNVQ3KM7:TR?= M1roUHNCVkeHUh?=
HC-1 Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTJ2LkW1OVEh|ryP NXu1T2F7W0GQR1XS
NCI-H2141 NXzFRVdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrMXotwUUN3ME2yOE44PzV2IN88US=> MkHoV2FPT0WU
MOLT-4 NWLPTG5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjxc5lKSzVyPUK2MlY4PTNizszN NV3Bd4hWW0GQR1XS
OMC-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1foU2lEPTB;MkeuNVQzOiEQvF2= NF;5SlNUSU6JRWK=
LC-1F M136cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHLSZpQUUN3ME2yO{4{OjR3IN88US=> NXvKXVVqW0GQR1XS
NCI-H1304 NF3VV2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTJ6LkG2Nlgh|ryP M1zXZ3NCVkeHUh?=
BC-1 NYLYe3V2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTJ6Lk[1NUDPxE1? NFjidWVUSU6JRWK=
NCI-H64 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TWO2lEPTB;MkmuOlI2OyEQvF2= MVXTRW5ITVJ?
MOLT-16 NFXFNmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPlR41KSzVyPUK5MlYzQTJizszN MoDjV2FPT0WU
U-87-MG M3SyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjWRoxKSzVyPUOwMlc3PiEQvF2= MkXhV2FPT0WU
GAK NVjlb4hNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTVOYpDUUN3ME2zNU4zPjh4IN88US=> MWnTRW5ITVJ?
ES8 M{fTb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHhWHZOUUN3ME2zNk4yOjV{IN88US=> Mn7MV2FPT0WU
HCC1599 NGXpb2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXMbXVKSzVyPUOyMlM{OjVizszN MX7TRW5ITVJ?
EB-3 NWTOVIJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWO2XHNXUUN3ME2zOE4{OTF5IN88US=> MnX4V2FPT0WU
HCC1187 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrWd3pKSzVyPUO1MlgxPTJizszN MVTTRW5ITVJ?
SK-PN-DW Mki2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTN4LkG5OFMh|ryP NEPiSItUSU6JRWK=
JVM-3 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XOTWlEPTB;M{euNlM{QCEQvF2= NV3hTI17W0GQR1XS
HCC2157 NIT3fmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTN5Lkm5OFYh|ryP NXPnZYpIW0GQR1XS
A4-Fuk MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYW3RXg{UUN3ME2zPE4yODB7IN88US=> M{\yXXNCVkeHUh?=
COR-L279 MnjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILjRY9KSzVyPUSwMlI5PTFizszN NV;UNmI6W0GQR1XS
DEL NGLTXnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUW5cJAzUUN3ME20NU46ODh4IN88US=> NIKzbJRUSU6JRWK=
NCI-H1395 NUPl[FRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDE[|VYUUN3ME20Nk4xOTZ|IN88US=> M{Pz[XNCVkeHUh?=
MHH-NB-11 MkXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTGZnRzUUN3ME20N{4xQDF6IN88US=> NHLHRW9USU6JRWK=
NCI-H2107 NGXDVoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TkR2lEPTB;NEOuOFg1PiEQvF2= MV\TRW5ITVJ?
NEC8 M1PrdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\kc|lKSzVyPUS0MlM{PiEQvF2= MUDTRW5ITVJ?
COLO-684 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3ZT2tKSzVyPUS2MlIzPThizszN NWXFNVRQW0GQR1XS
LS-411N M{XPcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGX6RVJKSzVyPUS4MlQ4PDhizszN M1u1bXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research:

[1]

+ Expand
  • Cell lines: Ba/F3 cell lines
  • Concentrations: ~32 nM
  • Incubation Time: 72 hours
  • Method:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (200.81 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage powder
in solvent
Synonyms BMS-354825

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01445509 Active, not recruiting Solid Tumors National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 27, 2008 Phase 1
NCT03041701 Not yet recruiting Rhabdomyosarcoma|Rhabdomyosarcoma- Alveolar|Rhabdomyosarcoma-Embryonal National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 24, 2017 Phase 1|Phase 2
NCT03023046 Not yet recruiting Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|CD20 Positive|Philadelphia Chromosome Positive University of Washington|National Cancer Institute (NCI) February 2017 Phase 2
NCT03020030 Not yet recruiting Acute Lymphoblastic Leukemia, Pediatric Dana-Farber Cancer Institute|Baxalta US Inc. January 2017 Phase 3
NCT02744768 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto December 2016 Phase 2
NCT02923986 Not yet recruiting Chronic Myelogenous Leukemia, Ph1-Positive Bio-Path Holdings, Inc. November 2016 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID